Specifically, one in calculating our benefit for income taxes resulted in the overstatement of our advantage for taxes by $4.1 million for the quarter.8 million from the previously disclosed quantity of $23.9 million.3 million, or a loss per common share of $4.67, from $365.2 million, or a reduction per common talk about of $4.62.2 from the previously disclosed amount of $28.3 million.7 million, or a loss per common talk about of $1.58, from $127.5 million, or a loss per common share of $1.53. The result of the correction increased our adjusted cash-basis provision for income taxes for the quarter from $30.2 million to $34.4 million, which led to a reduction of our altered cash-basis net gain per diluted common share for the fourth quarter of 2011 from $0.74 to $0.70.0 million to $112.1 million, which resulted in a reduced amount of our altered cash-basis net income per diluted common talk about for 2011 from $2.48 to $2.44..An effective clinical trial is one that produces a scientifically accurate result. It might not be the effect you had hoped for, but it answers queries that help the field progress. We applaud Merck’s incredible leadership on HIV vaccine analysis. The ongoing business has set an example for the field, dealing with probably the most important health technology problems of our period. Merck and its own collaborator, the united states NIH-funded HIV Vaccine Trials Network, have already been committed, willing and strategic to take risks at every stage of analyzing MRK-Ad5, and they must be commended for this.